Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Vaccine|December 8, 2007
Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderlyIris de Bruijn, Ingo Meyer, Lisya Gerez, et al.
Vaccine|February 13, 2019
Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the Northern and Southern HemispheresStephanie Pepin, Sandrine I Samson, Fabian P Alvarez, et al.
Vaccine|July 8, 2008
Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in ChinaFeng Cai Zhu, Weizhong Zhou, Hongxing Pan, et al.
Vaccine|April 18, 2026
Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised studyPedro M Folegatti, Stephanie Pepin, Cynthia Tabar, et al.
Human Vaccines & Immunotherapeutics|April 6, 2026
Immunogenicity and safety of an inactivated split-virion influenza vaccine in individuals 6 months of age and older in IndiaPedro M Folegatti, Cynthia Tabar, Celine Petit, et al.
Expert Review of Vaccines|November 22, 2017
Quadrivalent inactivated influenza vaccine (VaxigripTetra™)Viviane Gresset-Bourgeois, Phillip S Leventhal, Stéphanie Pepin, et al.
American Heart Journal|March 16, 2021
Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trialRosalind Hollingsworth, Arto Palmu, Stephanie Pepin, et al.
Vaccine|March 11, 2023
Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trialLeilani Sanchez, Takahiro Nakama, Hideaki Nagai, et al.
Influenza and Other Respiratory Viruses|April 3, 2024
High-Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older AdultsArto A Palmu, Stephanie Pepin, Ritva K Syrjänen, et al.
Human Vaccines & Immunotherapeutics|December 8, 2019
Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trialJoyce Ojeda, José Luis Arredondo, Perla Salcedo, et al.
Pageof 2